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Pedal peptides and orcokinins are structurally related neuropeptides that were first discovered in 22 
protostomian invertebrates - mollusks and arthropods, respectively. Recently, pedal peptide/ocokinin 23 
(PP/OK)-type neuropeptides were discovered in a deuterostomian phylum, the echinoderms, indicating that 24 
the evolutionary origin of this neuropeptide family can be traced back to the common ancestor of bilaterian 25 
animals. Sequences comparison of PP/OK-type neuropeptides reveals several conserved residues, including 26 
N- and C-terminally located hydrophobic residues that are important for the bioactivity of orcokinin. Here we 27 
report the first comprehensive analysis of the structure-activity relationships of a PP/OK-type neuropeptide – 28 
starfish myorelaxant peptide (SMP; FGKGGAYDPLSAGFTD) from the starfish Patiria 29 
pectinifera (Phylum Echinodermata). Comparison of the bioactivity of SMP with N-terminally and/or C-30 
terminally truncated and alanine-substituted SMP analogs revealed a core peptide (GAYDPLSAGF; SMP(5-31 
14)) that retains the muscle-relaxing activity of SMP, albeit with reduced potency and efficacy. Within this 32 
core peptide, alanine-substitution of several residues resulted in complete or partial loss of bioactivity, whilst 33 
loss or substitution of the N-terminal phenylalanine residue of SMP also caused a substantial reduction 34 
in bioactivity. Furthermore, analysis of the bioactivity of other SMP-like peptides derived from the same 35 
precursor as SMP revealed that none of these were more potent/effective than SMP as muscle relaxants. In 36 
conclusion, we have identified key residues required for the bioactivity of a PP/OK-type neuropeptide 37 
(SMP), including hydrophobic residues located in the N- and C-terminal regions that are conserved in PP/OK-38 
type peptides from other phyla as well as core residues that are conserved in echinoderm PP/OK-type peptides. 39 
 40 
Keywords: structure-activity relationship, starfish myorelaxant peptide, pedal peptide/orcokinin-type 41 
neuropeptide, truncated analog, alanyl-substitued analog, SMP-like peptide   42 
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1. Introduction 43 
Neuropeptides are neuronal signalling molecules that have key roles in the regulation of physiological 44 
processes and behaviour. The evolutionary origin of many neuropeptide signalling systems can be traced back 45 
to the common ancestor of bilaterian animals based on their occurrence in protostomes and deuterostomes [1, 46 
2]. One of the bilaterian neuropeptide families are pedal peptide/orcokinin-type peptides [2, 3]. Pedal peptide 47 
(PP) was first discovered in the mollusk Aplysia californica and named on account of its predominant 48 
expression in the pedal ganglia of the central nervous system in this species [4]. In accordance with its 49 
expression, PP causes an increase in the contraction of pedal muscles [5] and the beating of cilia associated 50 
with the foot [6], effects that are indicative of a physiological role in regulation of locomotor activity in 51 
gastropod mollusks. Meanwhile, orcokinin (OK) was originally isolated from neural extracts of the crayfish 52 
Orconectus limosus on account of its stimulatory effect on hindgut activity [7]. Furthermore, molecular 53 
characterization of OK-type neuropeptides in other arthropods, including insects, has revealed that multiple 54 
OK isoforms occur in each species [8] and the OK gene is alternatively spliced to give rise to two different 55 
transcripts that encode preproOK-A and -B [9-14]. Investigation of the actions of OK-type peptides has 56 
revealed diverse physiological roles, including effects on hindgut myoactivity in the crayfish O. limosus [7], 57 
stimulation of the prothoracic gland in the silk moth Bombyx mori [15, 16], and regulation of circadian 58 
locomotor activity in the cockroach Leucophaea maderae [17-19]. In addition, gene silencing studies using 59 
RNAi have revealed roles of OK-type peptides in regulation of “awakening” behavior in the beetle Tribolium 60 
castaneum [13], regulation of vitellogenin expression in the cockroach Blattella germanica [11], and 61 
regulation of ecdysis in the kissing bug Rhodnius prolixus [9]. Thus, PP/OK-type neuropeptides have been 62 
recruited to act as stimulators of the activity of muscle and other tissues in mollusks and arthropods. Through 63 
analysis of genome/transcriptome sequence data PP/OK-type neuropeptides have also been identified in other 64 
protostomian invertebrates such as annelids and nematodes [2, 3, 20], but nothing is known about the 65 
physiological roles of PP/OK-type peptides in these phyla. 66 
An important advance in our understanding of the evolution of PP/OK-type neuropeptides was the 67 
discovery of two genes/transcripts encoding PP/OK-type neuropeptide precursors in a deuterostomian 68 
invertebrate, the sea urchin Strongylocentrotus purpuratus (Phylum Echinodermata) [3]. Thus, it was 69 
established that PP/OK-type neuropeptides are a bilaterian neuropeptide family. Subsequently, a PP/OK-type 70 
neuropeptide precursor was identified in another echinoderm species, the sea cucumber Apostichopus 71 
japonicus [21]. Furthermore, an important insight into the physiological roles of PP/OK-type neuropeptides in 72 
echinoderms was made when it was discovered that a muscle-relaxing peptide in the starfish Patiria 73 
pectinifera (“starfish myorelaxant peptide”; SMP) is a PP/OK-type neuropeptide [22]. Thus, in contrast with 74 
the myoexcitatory actions of PP/OK-type neuropeptides in mollusks and arthropods, the relaxing effects of 75 
SMP on starfish muscle are indicative of a role as an inhibitory neuromodulator/neurotransmitter. Comparison 76 
of the sequence of SMP with other PP/OK-type neuropeptides reveals evolutionarily conserved structural 77 
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features [3, 21-29] (Fig. 1). A general characteristic of PP/OK-type peptides in both echinoderms and in 78 
protostomes are hydrophobic residues, typically phenylalanine, located proximal to or at the N- and C-termini 79 
of the peptides. A more specific feature of echinoderm PP/OK-type peptides is the core motif (D/E)-(P)-(L/M) 80 
[3, 21, 22]. 81 
Analysis of the structure-activity relationships of orcokinin (NFDEIDRSGFGFN) has revealed that N-82 
terminal truncation removing the phenylalanine residue at position 2 causes a complete loss of bioactivity. 83 
Furthermore, C-terminal truncation removing the phenylalanine residue at position 12 results in a 50% loss of 84 
bioactivity, whilst C-terminal truncation to the point where residue 10 (phenylalanine) is removed causes a 85 
complete loss of bioactivity [30]. Thus, N- and C-terminal phenylalanine residues appear to be important for 86 
the bioactivity of orcokinin. It is not known, however, if the structure-activity relationships of orcokinin are 87 
generally applicable to PP/OK-type peptides in other phyla.  88 
Nothing is known about the structure-activity relationships of SMP or other PP/OK-type peptides in 89 
echinoderms. To address these issues, here we have used in vitro pharmacology to analyze the structure-90 
activity relationships (SAR) of SMP. The apical muscle of P. pectinifera was used as a bioassay to assess the 91 
relative importance of each amino acid residue in the sequence of SMP, testing N- and C-terminally truncated 92 
analogs of SMP and testing analogs of SMP in which each residue was substituted with an alanine (i.e. an 93 
alanine scan).  94 
Many neuropeptide precursors, particularly in invertebrates, comprise multiple copies of structurally 95 
identical/similar peptides and this is also a feature of PP/OK-type peptide precursors, including the SMP 96 
precursor [3, 21, 25, 28]. Thus, the P. pectinifera SMP precursor comprises twelve copies of SMP (SMPa) and 97 
multiple copies of three other structurally related peptides: SMPb (5 copies), SMPc (1 copy), and SMPd (1 98 
copy) [22]. SMPa, SMPb, and SMPc have similar primary structures: FGKGGAYDPLSAGFTD, 99 
FGMGGAYDPLSAGFTD, and FGMGGAYDPLSAGFTE, respectively. Lysine at the third residue is 100 
substituted with methionine in both SMPb and SMPc and aspartic acid at the sixteenth residue is substituted 101 
with glutamate in SMPc. The amino acid sequence of SMPd (GFLHGPDDPLSTSFVDGD) is quite different to 102 
the SMP sequence, but the consensus features of echinoderm PP/OK-type peptides are nevertheless present in 103 
SMPd. The occurrence of multiple copies of identical or similar peptides is a characteristic of many 104 
neuropeptide precursors, particularly in invertebrates, but its functional significance is not fully understood 105 
[31-36]. The occurrence of multiple copies of a neuropeptide may be energetically efficient way of generating 106 
many messenger molecules from a single precursor protein. However, it is not clear why this feature has 107 
evolved in some neuropeptide precursors but not in others. Furthermore, the occurrence of “cocktails” of 108 
multiple isoforms of structurally related neuropeptides may enable neuropeptides derived from a single 109 
precursor protein to acquire different biophysical properties that are functionally important in a physiological 110 
context. To begin to address these issues for peptides derived from the P. pectinifera SMP precursor, here we 111 
have compared the bioactivity of SMPa with the bioactivity of SMPb, SMPc and SMPd. on three different in 112 
vitro preparations of starfish neuromuscular organs – apical muscle, tube feet and cardiac stomach. 113 
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Furthermore, we have also compared the bioactivity of SMPa with the bioactivity of a peptide “cocktail” 114 
comprising all of the peptides derived from the SMP precursor but at concentrations corresponding to their 115 
copy number in the precursor.   116 
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2. Materials and methods 117 
2.1. Animals 118 
Live specimens of the starfish Patiria pectinifera were collected at Cheongsapo of Busan, Korea, and 119 
maintained in a recirculating seawater system at 15 oC until use. The animals were fed once every three days 120 
with live manila clam, Ruditapes philippinarum. Approval by the local institution/ethics committee was not 121 
required for this work because experimental work on starfish is not subject to regulation. 122 
2.2. Peptide synthesis and purification 123 
SMP (SMPa), SMP-like peptides (SMPb, SMPc, and SMPd) derived from the P. pectinifera SMP 124 
precursor, N- and C-terminal truncated analogs of SMP, alanyl-substituted analogs of SMP, and a shortened 125 
SMP analog with alanyl-substitution were synthesized by a conventional solid-phase method with Fmoc-126 
protected amino acids and coupling reagents, 1-hydroxybenzotriazole (HOBT) and N,N-127 
diisopropylcarbodimide (DIPCI), using a peptide synthesizer (PSSM-8, Shimadzu), as described previously 128 
[22]. The synthetic peptides were first subjected to reversed phase (RP)-HPLC on a semi-preparative Vydac 129 
218TP510 Protein & Peptide C18 column (300 Å, 5 µm, 9.2 ×250 mm, USA). Elution was performed with a 130 
linear gradient of 10 to 30% acetonitrile/0.1% trifluoroacetic acid (TFA) at a flow rate of 3.0 ml/min for 40 131 
min. The peptides were lyophilized and re-chromatographed on an analytical Vydac 218TP54 Protein & 132 
Peptide C18 column (300 Å, 5 µm, 4.6 × 250 mm, USA) with an adequate acetonitrile gradient. Each purified 133 
peptide was analyzed on the same analytical column with isocratic conditions to confirm the desired purity 134 
(>98%). An aliquot of purified peptide were mixed with the same volume of α-cyano-4-hydroxycinnamic acid 135 
(10 mg/ml in 50% acetonitrile/0.1% TFA) and then 2 µl of each sample solution was spotted directly onto a 136 
MALDI sample plate. Molecular masses of the peptides were determined by matrix assisted laser desorption 137 
ionization–time of flight (MALDI-TOF) mass spectrometry (Voyager-DETM PRO spectrometer, Perseptive 138 
Biosystem) equipped with the following parameters: low mass gate set to 600 Da, mass range set to 0-6000 139 
Da, accelerating voltage set to 20 000 V, grid voltage set to 60.5% of accelerating voltage, grid wire set to 1.0 % 140 
of the accelerating voltage, and the delayed extraction time was set to 400 ns. Retention times of synthetic 141 
SMPa and SMP-like peptides (SMPb, SMPc and SMPd) were compared on RP-HPLC (Vydac 218TP54 Protein 142 
& Peptide C18 column, 300 Å, 5 µm, 4.6 × 250 mm, USA) with a linear gradient of 5 to 45% acetonitrile/0.1% 143 
TFA at flow rate 1 ml/min in 40 min and truncated SMP analogs were compared on the same RP-HPLC 144 
column with a linear gradient of 10 to 40% acetonitrile/0.1% TFA at flow rate 1 ml/min in 30 min. The 145 
retention times of alanyl-substituted SMP analogs were compared with an isocratic elution of 20% 146 
acetonitrile/0.1% TFA at a flow rate of 1.0 ml/min on the same RP-HPLC column. The primary sequences of 147 
N- and C-terminal truncated analogs of SMP, alanyl-substituted analogs of SMP and SMP-like peptides 148 
(SMPb, SMPc and SMPd) used in this study are listed in Table 1, 2, and 3, respectively. 149 
2.3. In vitro pharmacology 150 
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Three neuromuscular preparations (apical muscle, cardiac stomach, and tube feet) were dissected from P. 151 
pectinifera for investigation of the pharmacological activity of synthetic peptides according to previously 152 
reported methods [22]. Briefly, the apical muscle was cut from the aboral body wall of an arm, where the 153 
apical muscle forms a thickening of longitudinally orientated muscle that runs along the mid-line of the inner 154 
side. A piece of cardiac stomach between the oral opening and extrinsic retractor strand was obtained by 155 
removing the aboral body wall from the central disk and the proximal region. An individual whole tube foot 156 
was dissected from the arm ambulacra but without the ampulla. All muscle preparations were cut to 157 
approximately 10 mm, and both ends of the muscle preparations were tied with cotton threads. The 158 
preparations were then suspended vertically in a 2 ml polypropylene chamber containing artificial seawater 159 
(ASW) with aeration, one end being connected to a silver hook at the bottom of the chamber and the other to a 160 
force displacement transducer (Type 45196A, NEC-Sanei Instrument Ltd., Tokyo, Japan). Output from the 161 
force displacement transducer was monitored by a recorder (WR7300, GRAPHTEC CORP., Yokohama, 162 
Japan) via an amplifier (AS1302, NEC-Sanei, Tokyo, Japan), which recorded the mechanical responses of the 163 
device. Prior to testing, the muscle preparations were allowed to stabilize for about 90 min. The resting 164 
tension was adjusted to 1.0 g for apical muscle and 0.5 g for cardiac stomach and tube foot. Muscles in the 165 
chamber were allowed to equilibrate for about 30 min in ASW, during which ASW in the chamber was 166 
freshly replaced every 15 min. Pre-contraction of apical muscle, cardiac stomach or tube foot preparations was 167 
induced by applying 1 µM acetylcholine (ACh), 10 µM carbachol or 30 mM high-potassium ASW, 168 
respectively. Immediately after equilibration, the muscles were treated with test samples to measure relaxation 169 
responses, reflecting the original identification of SMP as a muscle relaxant in P. pectinifera using an in vitro 170 
muscle bioassay [22]. The pharmacological activity of SMP at a concentration range of 10-10 M (0.1 nM) to 171 
10-5 M (10 µM) was tested on three types of starfish muscles for 12 separate experiments at room temperature. 172 
For other synthetic analog peptides, at least 4 to 7 separate experiments were performed to test the activities 173 
using a concentration range of 10-10 M to 10-5 for most of peptides and a single concentration of 10-4 M (100 174 
µM) for shortened SMP analogs at room temperature. The effect of a “cocktail” of SMP-like peptides 175 
(SMPcocktail), mixed at a molar ratio of 12 (SMPa) : 5 (SMPb) : 1 (SMPc) : 1 (SMPd), on the three starfish 176 
neuromuscular preparations was also examined. The relaxing responses to peptides were normalized as the 177 
percentage reversal of the maximal contraction of apical muscle with 1 µM ACh, of cardiac stomach by 10 178 
µM carbachol or of tube foot by 30 mM high-potassium ASW containing 30 mM KCl, 445 mM NaCl, 10 mM 179 
CaCl2, and 55 mM MgCl2 adjusted to pH 7.8 with 20 mM Tris/HCl. 180 
2.4. Data analysis and statistics 181 
All data were expressed as the mean ± standard error of the mean (SEM). Concentration-response curves 182 
were fitted with nonlinear regression analysis and a sigmoidal curve of a four-parameter logistic equation with 183 
automatic outlier elimination using Prism software version 7.0 for Windows (GraphPad Software, San Diego, 184 
California, USA). The potency (EC50) and the efficacy (Emax) values for each peptide were calculated from the 185 
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best-fit of a sigmoidal concentration-response curve equation, where the potency (EC50) is represented with 186 
pEC50, the negative logarithm of the half maximal effective concentration of the peptide and Emax is the best-187 
fit top value on a concentration-response curve for peptide-induced relaxation. The relative activity (RA) of a 188 
SMP analog was calculated as the ratio of the concentration of SMP and the analog peptide required to 189 
produce equivalent effects corresponding to the half-maximal relaxation of SMP. Statistical comparison of 190 
pEC50 and Emax between data sets was performed using the Extra sum-of-squares F test [37]. The effects of 191 
SMP and SMP analogs at the highest concentration tested (10-5 M) were compared statistically using one-way 192 
analysis of variance (ANOVA) supported by Bonferroni’s multiple comparisons test. P values less than 0.05 193 
(p < 0.05) were considered as statistically significant. Generation of graphs, calculations and statistical 194 
analyses were performed using Prism software version 7.0 for Windows (GraphPad Software, San Diego, 195 
California, USA).   196 
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3. Results 197 
3.1. Effects of N-terminal truncation on the bioactivity of SMP as a muscle relaxant 198 
The importance of the N-terminal region of SMP for its bioactivity as a relaxant of apical muscle 199 
preparations was investigated using a series of truncated analogs that were truncated up to ten residues. 200 
Molecular masses of synthetic analogs corresponded with theoretically calculated masses and the retention 201 
times of each peptide were steadily reduced in accordance with stepwise truncation of residues from the N-202 
terminus (Table 1). With truncation of the first four residues from the N-terminus, the efficacy and relaxing 203 
activity (at 10-5 M) of analogs were comparable with full length SMP: thus, relative to SMP, the Emax and 204 
relaxing activity (at 10-5 M) values for SMP(2-16) were 112.4 ± 14.8% and 102.9 ± 3.6%, for SMP(3-16) 205 
were 108.3 ± 15.5% and 98.9 ± 8.4%, for SMP(4-16) were 110.6 ± 6.7% and 99.8 ± 7.3%, and for SMP(5-16) 206 
were 121.4 ± 6.2% and 113.4 ± 4.4%, respectively. However, removal of the first phenylalanine reside (Phe1) 207 
in SMP(2-16) caused a significant reduction in potency (pEC50 = -6.65 ± 0.28 M; n=5; p<0.0001) compared 208 
with full length SMP, whereas stepwise removal of residues to the fourth residue (Gly4) did not cause any 209 
further decrease in potency (Fig. 2A and Table 1). These data indicate the N-terminal Phe1 residue of SMP is 210 
important for the potency of SMP as a muscle relaxant, whereas residues at positions 2, 3 and 4 are less 211 
important for the potency of SMP. Analogs with further truncation from residues Gly5 to Pro9 (analogs: 212 
SMP(6-16), SMP(7-16), SMP(8-16), SMP(9-16), and SMP(10-16)) did not exhibit maximal muscle-relaxing 213 
activity at the high concentration tested (10-5 M) and exhibited significantly reduced bioactivity compared to 214 
SMP. Furthermore, an analog comprising only the C-terminal six residues of SMP, SMP(11-16), had no effect 215 
on apical muscle preparations (Fig. 2A). Thus, the relative activity for all N-terminally truncated analogs was 216 
steadily reduced in accordance with stepwise truncation of residues from the N-terminus of full length SMP. 217 
Collectively, these experiments indicate that SMP requires at least twelve amino acids from residue Gly5 to 218 
residue Asp16 to exhibit the same efficacy as SMP as a relaxant of apical muscle preparations, whilst the first 219 
Phe1 residue is required to retain potency equivalent to that of the full length SMP peptide. 220 
3.2. Effects of C-terminal truncation on the bioactivity of SMP as a muscle relaxant 221 
The importance of the C-terminal region of the SMP for its relaxing activity on apical muscle 222 
preparations was investigated by stepwise truncation of residues up to Ser11, the sixth residue from the C-223 
terminus (Fig. 2B and Table 1). SMP(1-15) and SMP(1-14) exhibited efficacies of 107.5 ± 7.5% and 106.3 ± 224 
6.2%, respectively, and relaxing activities (at 10-5 M) of 99.7 ± 2.2% and 102.9 ± 2.9%, respectively, which 225 
correspond with full length SMP. However, the potencies of SMP(1-15) and SMP(1-14) were approximately 226 
22-fold (pEC50 = -6.36 ± 0.12 M) and 9-fold (pEC50 = -6.76 ± 0.13 M) less than that of SMP, respectively. 227 
Accurate deconvolution values could not be obtained from the sigmoidal curve of SMP(1-13) because 228 
maximal relaxation was not observed with the highest concentration tested, but removal of the third residue 229 
(Phe14) from the C-terminus in the analog SMP(1-13) clearly caused a drastic reduction in bioactivity, 230 
including efficacy (31.3 ± 24.8%), potency (pEC50 = ~-5.69 ± ~3.30 M), and relative activity (0.00066), which 231 
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were approximately 3.7 fold, 100 fold and 1 500-fold less than those of full length SMP, respectively (see 232 
SMP(1-13) concentration-response curve in Fig. 2B). This result demonstrates that the Phe14 residue in the C-233 
terminal region of SMP is a critical residue for the bioactivity of full length SMP as a relaxant of the P. 234 
pectinifera apical muscle. Removal of the fourth residue (Gly13) from C-terminus in the analog SMP(1-12) led 235 
to an almost complete loss of activity, an effect greater than that seen with SMP(7-16), which lacks nine 236 
residues from the N-terminus. Thus, the bioactivity of SMP is more adversely affected by C-terminal 237 
truncation than by N-terminal truncation. Collectively, these data indicate that the C-terminal region of SMP, 238 
and in particular Phe14, is critical for the bioactivity of SMP as a muscle relaxant. 239 
3.3. Effect of combined N- and C-terminal truncation on the bioactivity of SMP 240 
Informed by the results from experiments with N- and C-terminal truncated analogs, an N-terminally and 241 
C-terminally truncated analog of SMP comprising ten amino acids, SMP(5-14), was designed, synthesized 242 
and tested on apical muscle preparations as a predicted minimal bioactive analog of SMP (Fig. 2C and Table 243 
1). SMP(5-14) exhibited potency (pEC50 = -4.41 ± 0.85 M) that was approximately 60-fold, 220-fold, or 2 244 
000-fold less than SMP (5-16), SMP (1-14) and full length SMP, respectively. Thus, the relative activity of 245 
SMP(5-14) was approximately 20-fold, 50-fold, and 440-fold less than SMP (5-16), SMP (1-14) or full length 246 
SMP, respectively. Although the relaxing activity at 10-5 M of SMP (5-14) only reached half of that of SMP 247 
(62.3 ± 5.6%), its efficacy as determined by maximal response was 150.1 ± 54.0%, which was not statistically 248 
different to that of SMP. These results indicate that SMP (5-14), comprising the ten amino acids from Gly5 to 249 
Phe14 of full length SMP, is sufficient to elicit a maximal response when tested for its relaxing activity on 250 
apical muscle preparations.  251 
3.4. The effects of alanyl-substitution on the bioactivity of SMP 252 
Substitution of each amino acid residue by an alanine moiety is a classical approach to investigate the 253 
contributions of individual side chains to the structural and functional properties of proteins and peptides. 254 
Therefore, to examine the importance of each residue in SMP, a series of alanyl-substituted analogs were 255 
synthesized and tested for their effectiveness as relaxants of the apical muscle from P. pectinifera (Fig. 3 and 256 
Table 2). SMP is a sixteen residue peptide but only fourteen alanyl-substituted analogs were synthesized and 257 
tested because alanine itself is present in the primary sequence of SMP at two positions – Ala6 and Ala12. Like 258 
SMP, all of the alanyl-substituted analogs caused concentration-dependent relaxation of apical muscle 259 
preparations. The efficacies of the analogs were similar to SMP, with the exception of analogs with alanine 260 
substituted at Leu10, Gly13, and Phe14, which had lower efficacy and/or non-sigmoidal concentration-response 261 
curves (Fig. 3). In comparison with SMP, a significant decrease in relaxing activity (when tested at 10-5 M) 262 
was only observed with 10Ala-SMP (61.7 ± 4.9%; p<0.001) and 14Ala-SMP (46.8 ± 3.8%; p<0.0001). 263 
Substitution of five residues in the N-terminal region of SMP (Phe1 to Gly5) with alanine resulted in a 264 
significant reduction in potency (pEC50) in three analogs – 1Ala-SMP (pEC50 = -6.68 ± 0.15 M; p<0.0001), 265 
2Ala-SMP (pEC50 = -6.95 ± 0.40 M; p<0.05) and 5Ala-SMP (pEC50 = -6.89 ± 0.14 M; p<0.0001). The lowest 266 
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relative activity was exhibited by 1Ala-SMP (0.053), where Phe1 was replaced with Ala (Fig. 3A and Table 2). 267 
By contrast, drastic changes in activity were observed when alanine was substituted for residues (Tyr7 to Leu10) 268 
in the central region of SMP. All four analogs (7Ala-, 8Ala-, 9Ala-, and 10Ala-SMP) exhibited a significant 269 
reduction in potency with pEC50 in the range -6.71 ± 0.13 M to -4.64 ± 2.8 M, corresponding to approximately 270 
10 – 1 150 fold less than SMP. Among these, 10Ala-SMP in which Leu10 is substituted with alanine exhibited 271 
a remarkably drastic decrease in the potency (pEC50 = -4.64 ± 2.76 M) corresponding to 1 150-fold less than 272 
SMP and a relative activity 270-fold (0.0037) less than SMP (Fig. 3B and Table 2). The most deleterious 273 
impact on bioactivity was observed in the analog 14Ala-SMP, which exhibited an approximately 49 000-fold 274 
reduction in potency (pEC50 = ~-3.01 ± ~14.18 M), and a 550-fold reduction in bioactivity (0.0018) compared 275 
to SMP (Fig. 3C and Table 2). The similar activity exhibited by analogs with substitution of the four residues 276 
in the N-terminal region of SMP (Phe1 to Gly4) suggests that the side chains in this region may not be 277 
intimately involved in binding with receptor proteins. However, the remarkably drastic reduction in activity 278 
caused by substitution of four residues in the central region (Tyr7 to Leu10) and Phe14 at the C-terminus 279 
suggests that the side chains of these residues may have important roles in binding of SMP to its receptor(s).  280 
3.5. The effects of alanyl-substitution on the bioactivity of SMP(5-14) 281 
To further investigate the importance of the central region and residue Phe14 for the bioactivity of SMP, 282 
analogs with alanyl-substitution of each residue in the minimized SMP(5-14) peptide were synthesized and 283 
tested at 10-4 M on apical muscle preparations. Substitution of Gly5 and Tyr7 with alanine did not cause a 284 
significant reduction in bioactivity. However, substitution of residues from Asp8 to Phe14 with alanine caused 285 
a significant reduction in bioactivity (Fig. 4). Thus, consistent with the results from truncation and alanyl-286 
substitution of full-length SMP, these findings indicate that residues in the central region of SMP and the C-287 
terminal Phe14 of SMP are required to bind to and/or activate the SMP receptor(s) to elicit relaxation of the 288 
apical muscle of P. pectinifera.  289 
3.6. SMP is the most potent muscle-relaxing peptide derived from the SMP precursor 290 
The SMP precursor gives rise to SMP and three SMP-like peptides: SMP (SMPa, 12 copies), SMPb (5 291 
copies), SMPc (1 copy), and SMPd (1 copy) (Table 3) [22]. Therefore, we compared the bioactivity of SMP 292 
with the other three peptides and a mixture of the four peptides (SMPcocktail; containing SMP, SMPb, SMPc, 293 
and SMPd at a molar ratio of 12:5:1:1 corresponding to copy number in the precursor protein) at a range of 294 
concentrations on apical muscle preparations from the starfish P. pepctinifera. (Fig. 5 and Table 3). All four 295 
peptides and the SMPcocktail caused concentration-dependent relaxation of the apical muscle, and the efficacy 296 
(Emax), potency (pEC50) and relative activity were determined (Fig. 5A and Table 3). The efficacies of the four 297 
peptides and the SMPcocktail were not significantly different (p > 0.05; Table 3). The potencies of SMP, SMPb, 298 
and SMPcocktail were similar (pEC50 = -7.70 ± 0.07 M, -7.53 ± 0.09 M, and -7.48 ± 0.09 M, respectively) and 299 
were significantly more potent than SMPc (pEC50 = -7.38 ± 0.09 M) and SMPd (pEC50 = -6.33 ± 0.16), 300 
although an accurate deconvolution for statistical comparison between SMP and SMPd was not possible. The 301 
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relaxing activity of the peptides at the highest concentration tested (10-5 M) was determined as 120.3 ± 6.6% 302 
(SMP), 109.9 ± 4.3% (SMPb), 116.5 ± 8.3% (SMPc), 70.1 ± 4.0% (SMPd), and 124.2 ± 3.6% (SMPcocktail), with 303 
SMPd significantly less effective than the other peptides and the SMPcocktail (p<0.0001). The rank order of 304 
relative activity (RA) was as follows: SMP (1.0), SMPcocktail (0.80), SMPb (0.49), SMPc (0.49), and SMPd 305 
(0.0088). These data indicate that, consistent with its relative abundance, SMP is functionally the most 306 
important peptide derived from the SMP precursor as a relaxant of the apical muscle from P. pectinifera. 307 
To obtain further insights into the relative bioactivities of peptides derived from the SMP precursor, 308 
SMPa, SMPb, SMPc, SMPd and SMPcocktail were also tested on cardiac stomach and tube foot preparations from 309 
P. pectinifera (Fig. 5B). Administration of SMPa and the other peptides caused relaxation of both preparations. 310 
However, the potency, efficacy, and relative activity of each peptide were not calculated because maximal 311 
activity was not observed at the highest concentration tested (10-4 M), resulting in concentration-response 312 
curves that did not correspond to a sigmoidal curve with a four parametric equation. Therefore, the relaxing 313 
activities of the peptides on cardiac stomach and tube feet at 10-5 M were used for comparison but these were 314 
found not to be significantly different (Fig. 5B).       315 
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4. Discussion 316 
Starfish myorelaxant peptide (SMP) belongs to the bilaterian family of pedal peptide/orcokinin (PP/OK)-317 
type neuropeptides. Alignment of SMP with other PP/OK-type neuropeptides reveals interphyletic 318 
conservation of hydrophobic phenylalanine or leucine residues in the N-terminal and C-terminal regions. 319 
Furthermore, a core motif, (D/E)-(P)-(L/M), is a conserved feature of SMP-like peptides in echinoderms (Fig. 320 
1). However, the functional importance of these conserved residues for the bioactivity of SMP as a muscle 321 
relaxant is unknown. To address this issue here we investigated the structure-activity relationships of SMP 322 
from the starfish P. pectinifera. This is the first study to investigate the structure-activity relationships of a 323 
PP/OK-type neuropeptide in a deuterostome. 324 
Two approaches to investigation of the structure-activity relationships of SMP were employed here: 325 
firstly, N- and/or C-terminal truncation (Table 1 and Fig. 2) and secondly alanine substitution (Table 2 and Fig. 326 
3). It should be recognized, however, that there are limitations in these approaches toward identification of 327 
residues that are important for peptide bioactivity. The impact of alanine substitution on peptide bioactivity 328 
will to some extent be dependent on the choice of alanine as the substituting amino acid. Thus, replacement of 329 
residues that are structurally similar to alanine (e.g. glycine, valine) may have less impact on bioactivity than 330 
replacement of residues that are structurally dissimilar to alanine. So if replacement of a residue that is 331 
structurally similar to alanine has little on no impact on bioactivity, it doesn’t necessarily imply that the 332 
replaced residue is not important for peptide bioactivity.  333 
N-terminal and C-terminal truncation of SMP revealed a core peptide (GAYDPLSAGF; SMP(5-14)) that 334 
retains the muscle-relaxing activity of SMP, albeit with reduced potency and efficacy. Furthermore, stepwise 335 
N-terminal or C-terminal truncation of SMP revealed dramatic reductions in bioactivity with the loss of 336 
several key residues. Thus, in the N-terminal region loss of the first residue (Phe1) resulted in a ten-fold 337 
reduction in potency. Accordingly, substitution of Phe1 with alanine resulted in a twenty-fold reduction in 338 
potency and relative activity compared to SMP. However, stepwise loss of N-terminal residues up to position 339 
five (Gly5) resulted in no or only slight additional reductions in potency. Loss of the C-terminal residues Thr15 340 
and/or Asp16 caused an approximately ten-fold reduction in potency and relative activity, but loss of Phe14 341 
caused a much greater reduction in bioactivity corresponding to a relative activity of 0.00066 compared to 342 
SMP. Accordingly, substitution of Phe14 with alanine also caused a large reduction in bioactivity that 343 
corresponded to a relative activity of 0.0018 compared to SMP. Importantly, these findings are consistent with 344 
a previous investigation of the structure-activity relationships of the crustacean neuropeptide orcokinin 345 
(NFDEIDRSGFGFN) (Bungart et al., 1995). Here N-terminal truncation removing the first two residues, 346 
including Phe2 caused a complete loss of bioactivity, whilst C-terminal truncation removing the last two 347 
residues, including Phe12, caused a 50% reduction in bioactivity. Thus, experimental studies in both a 348 
protostome (orcokinin in the crayfish Orconectes limosus; Bungart et al., 1995) and a deuterostome (SMP in 349 
the starfish P. pectinifera; this study) have independently demonstrated the importance of N-terminal and C-350 
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terminal phenylalanines for the bioactivity of PP/OK-type peptides. These findings are consistent with the 351 
evolutionary conservation of N-terminal and C-terminal hydrophobic residues (Phe or Leu) in PP/OK-type 352 
peptides. 353 
Analysis of the core bioactive region of SMP GAYDPLSAGF also revealed the importance of several 354 
residues for the bioactivity of SMP (Fig. 4). Thus, substitution of residues Tyr7, Asp8, Pro9 and Leu10 with 355 
alanine produced peptides with relative activities of 0.053, 0.083, 0.027 and 0.0037, respectively, in 356 
comparison with SMP (Table 2 and Fig. 3). The least active of these analogs, 10Ala-SMP, is noteworthy 357 
because the presence of a hydrophobic residue in the position occupied by leucine at position ten in SMP is an 358 
evolutionarily conserved feature of all PP/OK-type peptides (Fig. 1). Accordingly, loss of the corresponding 359 
residue (Phe) in C-terminally truncated analogs of orcokinin results in a complete loss of bioactivity (Bungart 360 
et al., 1995). Thus, together with Phe1 and Phe14, Leu10 in SMP is one of three evolutionarily conserved 361 
hydrophobic residues that have been identified as important for bioactivity in both protostomian (orcokinin) 362 
and deuterostomian (SMP) PP/OK-type neuropeptides (Fig. 1 and 6). The other three residues in the core 363 
bioactive region of SMP (Tyr7, Asp8, Pro9) are not conserved in protostomian PP/OK-type peptides (see Fig. 364 
1). However, these residues are conserved in SMP-like peptides in other echinoderms. Therefore, these 365 
residues may be key residues in SMP that are important for receptor binding and activation. 366 
Precursors of PP/OK-type neuropeptides comprise multiple copies of structurally identical or similar 367 
bioactive peptides. For example, the precursor of the prototypical pedal peptide in Aplysia californica 368 
(GenBank Accession number: NP_001191585.1) comprises seventeen copies of pedal peptide and one copy 369 
each of two other pedal peptide-like neuropeptides [25] and the orcokinin precursor in the crayfish 370 
Procambarus clarkii (GenBank Accession number: BAA94754.1) comprises eight copies of orcokinin and 371 
four copies of three other orcokinin-like peptides [28]. Accordingly, the P. pectinifera SMP precursor 372 
comprises twelve copies of SMP (SMPa; FGKGGAYDPLSAGFTD), five copies of SMPb 373 
(FGMGGAYDPLSAGFTD), one copy of SMPc (FGMGGAYDPLSAGFTE) and one copy of SMPd 374 
(GFLHGPDDPLSTSFVDGD) [22]. Here we investigated the functional significance of the “cocktail” of 375 
neuropeptides derived from the SMP precursor by comparing the bioactivity of SMP (SMPa) with the 376 
bioactivities of SMPb, SMPc, SMPd and a “cocktail” (SMPcocktail) of all of the peptides derived from the SMP 377 
precursor mixed proportionately to peptide copy number in the precursor (Table 3 and Fig. 5 and 6). The 378 
potency of SMPb was not significantly different to that of SMPa but the relative activity of SMPb compared to 379 
SMPa was determined as 0.49. However, SMPb only differs from SMPa at one position – Lys3 in SMPa is 380 
replaced with Met in SMPb. Accordingly, substitution of Lys3 with alanine in the SMP analog 3Ala-SMP 381 
yielded a peptide with a potency that was not significantly different to SMP and that had a relative activity of 382 
0.38. SMPc has two amino-acid substitutions with respect to SMPa – Lys3 and Asp16 in SMPa are replaced with 383 
Met and Glu, respectively. SMPc exhibited a slight but significant reduction in potency compared to SMPa and 384 
relative activity of 0.39. Thus, although substitution of Asp16 with Glu represents a conservative substitution 385 
with another amino acid, it nevertheless caused a reduction in bioactivity. The sequence SMPd is quite 386 
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different to that of SMPa, with only seven of the sixteen residues in SMPa conserved in SMPd. The bioactivity 387 
of SMPd as an apical muscle relaxant was substantially less than that of SMPa, with a calculated relative 388 
activity of 0.0088. Lastly, the potency of the cocktail of SMP precursor derived peptides (SMPcocktail) was not 389 
significantly different to that of SMPa but SMPcocktail had a relative activity of 0.8. Thus, the bioactivity of 390 
peptides derived from the SMP precursor is largely attributable to SMPa. 391 
In conclusion, comparison of the bioactivity of analogs of SMP and SMP-like peptides derived from the 392 
SMP precursor has provided important new insights into functional significance of evolutionarily conserved 393 
residues in PP/OK-type neuropeptides. Furthermore, knowledge of the structure-activity relationships of 394 
PP/OK-type peptides may be useful in informing the design of compounds that could have applications for 395 
chemical control of invertebrate pests and parasites. An important goal for future studies will be to identify the 396 
receptor(s) that mediate the effects of PP/OK-type neuropeptides, which may enable identification of amino 397 
acids that form ligand binding sites for PP/OK-type peptides.  398 
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Figure legends 495 
 496 
Fig. 1. Multiple sequence alignment of PP/OK-type peptides in echinoderms and protostomes.  497 
White letters with grey or black highlighted boxes represent the conserved hydrophobic residues (Phe, Leu, 498 
Val, and Met) in PP/OK-type peptides. A specific feature conserved in echinoderm PP/OK-type peptides, the 499 
core motif (D/E)-(P)-(L/M), is underlined in blue. Lower case “a” in peptide sequences denotes a C-terminal 500 
amide group. Species abbreviations: Pp, Patiria pectinifera; Ar, Asterias rubens; Sp, Strongylocentrotus 501 
purpuratus; Aj, Apostichopus japonicus; Ac, Aplysia californica; Pd, Platynereis dumerilii; Ce, 502 
Caenorhabditis elegans; Nv, Nasonia vitripennis; Pc, Procambrus clarkii; Bg, Blattella germanica.  503 
 504 
Fig. 2. Concentration-responses curves comparing the effects of SMP and truncated analogs of SMP as 505 
relaxants of the apical muscle from P. pectinifera. The effect of SMP is compared with the effects of N-506 
terminally truncated analogs (A), C-terminally truncated analogs (B), and a minimized bioactive analog 507 
SMP(5-14) (C). Each point represents the mean ± standard error of the mean (SEM) determined from at least 508 
4 or 5 separate experiments and the curves were fitted with nonlinear regression analysis and a sigmoidal 509 
curve of a four-parameter logistic equation with automatic outlier elimination using Prism software (ver.7.0). 510 
The percentage relaxing activity was calculated by comparing each relaxation effect with the maximal 511 
contraction of the apical muscle by 1 µM ACh. 512 
 513 
Fig. 3. Concentration-responses curves comparing the effects of SMP and a series of alanyl-substituted 514 
analogs of SMP as relaxants of the apical muscle from P. pectinifera. Fourteen residues in the primary 515 
sequence of SMP (FGKGGAYDPLSAGFTD) were substituted with alanine: five residues (Phe1 to Gly5) in 516 
the N-terminal region (A), four residues (Tyr7 to Leu10) in the central region (B), and five residues (Ser11 to 517 
Asp16) in the C-terminal region (C). Each point represents the mean ± SEM determined from at least 4 to 7 518 
separate experiments and the curves were fitted with nonlinear regression analysis and a sigmoidal curve of a 519 
four-parameter logistic equation with automatic outlier elimination using Prism software (ver.7.0). The 520 
percentage relaxing activity was calculated by comparing each relaxation effect with the maximal contraction 521 
of the apical muscle by 1 µM ACh. 522 
 523 
Fig. 4. Graph comparing the effect of alanyl-substitution on the relaxing activity of minimized SMP(5-14) 524 
peptide (GAYDPLSAGF). Each point represents the mean ± SEM relaxing activity of peptides at 10-4 M on 525 
apical muscle preparations, determined from at least 4 to 6 separate experiments. Statistical analysis was 526 
performed by one-way ANOVA with Bonferroni’s multiple comparison test and significant differences 527 
between the effects of SMP(5-14) and its alanyl-substituted analogs is represented by n.s. (not significant) or 528 
asterisks (*p<0.05 and ****p<0.0001).  529 
Fig. 5. Comparison of the effects of SMP (SMPa), three SMP-like peptides and a mixture of the four peptides 530 
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(SMPcocktail; containing SMP, SMPb, SMPc, and SMPd at a molar ratio of 12:5:1:1 corresponding to copy 531 
number in the precursor SMP [22]) on three muscle preparations from P. pectinifera. All four peptides and the 532 
SMPcocktail caused concentration-dependent relaxing effects on the apical muscle (A). The peptides (at 10-5 M) 533 
were also tested on cardiac stomach and tube feet preparations and “n.s.” denotes that the relaxing effects of 534 
the peptides on these preparartions was not significantly different (B). Percentage relaxing activity was 535 
calculated by comparing each relaxation effect with the maximal contraction of apical muscle by 1 µM ACh, 536 
cardiac stomach by 10 µM carbachol, and tube feet by 30 mM high-potassium ASW, respectively. Data 537 
represent the mean ± SEM determined from five separate experiments.  538 
 539 
Fig. 6. Summary of the structure-activity relationships of SMP and identification of key residues for SMP 540 
bioactivity, including hydrophobic residues (red letters, Phe1, Leu10, and Phe14) located in the N- and C-541 
terminal regions that are conserved in PP/OK-type peptides in other phyla as well as core residues (blue letters, 542 
Tyr7, Asp8, and Pro9) that are only conserved in echinoderm PP/OK-type peptides. 543 
  544 
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Table legends 545 
 546 
Table 1 Physicochemical properties and pharmacological activities of N- and C-terminal truncated SMP 547 
analogs on the apical muscle of starfish P. pectinifera 548 
 549 
Table 2 Physicochemical properties and pharmacological activities of alanyl-substituted SMP analogs on the 550 
apical muscle of starfish P. pectinifera 551 
 552 
Table 3 Physicochemical properties and pharmacological activities of SMP-like peptides and SMP cocktail on 553 
the apical muscle of starfish P. pectinifera. 554 
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Graphical Abstract 555 
 556 
 557 
Starfish myorelaxant peptide (SMP) belongs to a bilaterian family of pedal peptide/orcokinin (PP/OK)-type 558 
neuropeptides that have evolutionarily conserved structural features. Here we report the first analysis of the 559 
structure-activity relationships of SMP and identify key residues for SMP bioactivity, including hydrophobic 560 
residues located in the N- and C-terminal regions that are conserved in PP/OK-type peptides in other phyla as 561 
well as core residues that are only conserved in echinoderm PP/OK-type peptides. 562 
23 
 
























Figure 6. 577 
 578 
Table 1 
Physicochemical properties and pharmacological activities of N- and C-terminal truncated SMP analogs on the apical muscle of starfish P. pectinifera 
Peptide Sequence Physicochemical property  Pharmacology aMrcalc. (M) bMrobs. (M+H)+ cRT (min)  dn eOutlier fpEC50 ± SEM, M (hp value) gEmax ± SEM, % (hp value) iRA 
SMP FGKGGAYDPLSAGFTD 1602.72 1603.53 27.28  12 4/72 -7.70 ± 0.07 114.7 ± 3.0 1.0 
N-terminal truncated analogs          
SMP(2-16) GKGGAYDPLSAGFTD 1455.54 1457.62 25.43  5 0/30 -6.65 ± 0.29 (<0.0001) 112.4 ± 14.8 (0.8613) 0.11 
SMP(3-16) KGGAYDPLSAGFTD 1398.49 1400.52 25.57  4 0/24 -6.39 ± 0.35 (†CBD) 108.3 ± 15.5 (0.6737) 0.059 
SMP(4-16) GGAYDPLSAGFTD 1270.32 1272.90 26.13  5 5/30 -6.65 ± 0.13 (<0.0001) 110.6 ± 6.7 (0.5764) 0.098 
SMP(5-16) GAYDPLSAGFTD 1213.27 1215.69 26.31  5 4/30 -6.17 ± 0.07 (<0.0001) 121.4 ± 6.2 (0.2958) 0.039 
*SMP(6-16) AYDPLSAGFTD 1156.21 1159.03 26.24  4 2/24 CBD CBD 0.013 
*SMP(7-16) YDPLSAGFTD 1085.14 1087.96 25.73  5 0/30 CBD CBD 0.0065 
*SMP(8-16) DPLSAGFTD 921.96 923.46 22.44  4 0/24 CBD CBD 0.0011 
*SMP(9-16) PLSAGFTD 806.87 808.29 20.14  4 2/24 CBD CBD 0.0058 
*SMP(10-16) LSAGFTD 709.75 711.09 18.69  4 2/24 CBD CBD 0.00046 
C-terminal truncated analogs          
SMP(1-15) FGKGGAYDPLSAGFT 1487.63 1490.12 27.91  4 2/24 -6.36 ± 0.12 (<0.0001) 107.5 ± 7.5 (0.4250) 0.038 
SMP(1-14) FGKGGAYDPLSAGF 1386.53 1389.28 29.17  4 2/24 -6.76 ± 0.13 (<0.0001) 106.3 ± 6.2 (0.2482) 0.11 
*SMP(1-13) FGKGGAYDPLSAG 1239.35 1241.89 23.21  5 6/30 CBD CBD 0.00066 
*SMP(1-12) FGKGGAYDPLSA 1182.30 1184.61 23.77  4 0/28 CBD CBD 0.00067 
*SMP(1-11) FGKGGAYDPLS 1111.22 1112.46 22.74  4 0/28 CBD CBD 0.00016 
*SMP(1-10) FGKGGAYDPL 1024.14 1025.43 24.17  5 1/30 CBD CBD 0.000092 
Shortened SMP          
*SMP(5-14) GAYDPLSAGF 999.44 997.52 28.36  5 1/35 -4.41 ± 0.85 (CBD) 150.1 ± 54.0 (0.3399) 0.0023 
aMrcalc., calculated average molecular mass by ExPASy Compute pI/Mw; bMrobs., observed protonated molecular mass on MALDI-TOF mass spectrophotometer; cRT, 
retention times determined on a reverse-phase C18 Vydac column (4.6 × 250 mm) with a linear gradient of 10 to 40% acetonitrile/0.1% TFA at a flow rate of 1.0 ml/min in 
30 min; dthe number of separate experiments; enumber of automatically eliminated data points per total number of data points for tested peptide; fpEC50, the negative 
logarithm of the half maximal effective concentration of the peptide, were calculated from the best-fit of a sigmoidal dose-response curve with a four-parameter logistic 
equation; gEmax, efficacy refers to the best-fit top value on a dose-response curve produced by the test peptide and is expressed as a relative percentage of the maximum 
contraction by 1 µM ACh; hp values were obtained by comparison of the best-fit values of pEC50 or Emax between SMP and truncated analog peptides using Extra sum-of-
squares F test and the values less than 0.05 (p < 0.05) were considered as statistically significant; iRA, relative activity was calculated as the ratio of the concentration of SMP 
and analog peptides required to produce equieffective responses to a half-maximal SMP response. *maximal relaxing activity was not reached at a peptide concentration of 
10-5 M. †CBD (cannot be determined) because the value was ambiguous and accurate deconvolution was not possible. 
Table 2 
Physicochemical properties and pharmacological activities of alanyl-substituted SMP analogs on the apical muscle of starfish P. pectinifera 
Peptide Sequence 
Physicochemical property  Pharmacology 
aMrcalc. (M) bMrobs. (M+H)+ cRT (min)  dn eOutlier fpEC50 ± SEM, M (hp value) gEmax ± SEM, % (hp value) iRA 
SMP FGKGGAYDPLSAGFTD 1602.72 1603.53 15.84  12 4/72 -7.70 ± 0.07 114.7 ± 3.0 1.0 
1Ala-SMP AGKGGAYDPLSAGFTD 1526.62 1527.46 11.25  6 8/36 -6.68 ± 0.15 (<0.0001) 119.8 ± 16.8 (0.1553) 0.053 
2Ala-SMP FAKGGAYDPLSAGFTD 1616.75 1617.65 15.01  5 3/30 -6.95 ± 0.40 (0.0100) 129.2 ± 24.0 (0.3420) 0.31 
3Ala-SMP FGAGGAYDPLSAGFTD 1545.63 1546.79 22.39  5 3/30 -7.34 ± 0.30 (0.1801) 114.9 ± 15.8 (0.9851) 0.38 
4Ala-SMP FGKAGAYDPLSAGFTD 1616.75 1616.76 17.53  5 2/30 -7.57 ± 0.14 (0.4139) 106.1 ± 5.9 (0.2696) 0.49 
5Ala-SMP FGKGAAYDPLSAGFTD 1616.75 1618.81 17.40  5 1/30 -6.89 ± 0.14 (<0.0001) 109.2 ± 7.1 (0.5026) 0.14 
7Ala-SMP FGKGGAADPLSAGFTD 1510.62 1512.65 11.52  5 3/30 -6.71 ± 0.13 (<0.0001) 101.6 ± 7.0 (0.1105) 0.053 
8Ala-SMP FGKGGAYAPLSAGFTD 1558.71 1560.97 13.44  7 4/42 -6.32 ± 0.32 (<0.0001) 134.5 ± 21.5 (0.1676) 0.083 
*9Ala-SMP FGKGGAYDALSAGFTD 1576.68 1578.45 12.95  4 0/24 -5.72 ± 0.50 (†CBD) 144.1 ± 38.6 (0.1940) 0.027 
*10Ala-SMP FGKGGAYDPASAGFTD 1560.64 1562.32 7.49  5 0/30 -4.64 ± 2.76 (CBD) 148.3 ± 199.3 (0.8038) 0.0037 
11Ala-SMP FGKGGAYDPLAAGFTD 1586.72 1588.19 19.69  5 0/30 -7.10 ± 0.39 (0.0635) 129.7 ± 26.4 (0.4090) 0.30 
*13Ala-SMP FGKGGAYDPLSAAFTD 1616.75 1618.43 28.36  4 3/24 CBD CBD 0.15 
*14Ala-SMP FGKGGAYDPLSAGATD 1526.62 1528.50 8.07  6 0/36 CBD CBD 0.0018 
15Ala-SMP FGKGGAYDPLSAGFAD 1572.69 1573.60 17.00  5 2/30 -7.40 ± 0.13 (0.0719) 114.9 ± 8.3 (0.9775) 0.31 
16Ala-SMP FGKGGAYDPLSAGFTA 1558.71 1560.70 20.90  4 0/24 -6.93 ± 0.24 (0.0006) 113.2 ± 12.7 (0.8999) 0.16 
aMrcalc., calculated average molecular mass by ExPASy Compute pI/Mw; bMrobs., observed protonated molecular mass on MALDI-TOF mass spectrophotometer; cRT, 
retention times determined on a reverse-phase C18 Vydac column (4.6 × 250 mm) with an isocratic elution of 20% acetonitrile/0.1% TFA at a flow rate of 1.0 ml/min; 
dthe number of separate experiments; enumber of automatically eliminated data points per total number of data points for tested peptide; fpEC50, the negative logarithm of 
the half maximal effective concentration of the peptide, were calculated from the best-fit of a sigmoidal dose-response curve with a four-parameter logistic equation; gEmax, 
efficacy refers to the best-fit top value on a dose-response curve produced by the test peptide and is expressed as a relative percentage of the maximum contraction by 1 
µM ACh; hp values were obtained by comparison of the best-fit values of pEC50 or Emax between SMP and alanine substituted analog peptides using Extra sum-of-squares 
F test and the values less than 0.05 (p < 0.05) were considered as statistically significant; iRA, relative activity was calculated as the ratio of the concentration of SMP and 
analog peptides required to produce equieffective responses to a half-maximal SMP response. *maximal relaxing activity was not reached at a peptide concentration of 10-
5 M. †CBD (cannot be determined) because the value was ambiguous and accurate deconvolution was not possible. 
 
Table 3 
Physicochemical properties and pharmacological activities of SMP-like peptides and SMP cocktail on the apical muscle of starfish P. pectinifera 
Peptide Sequence 
Physicochemical property  Pharmacology 
aMrcalc. (M) bMrobs. (M+H)+ cRT (min)  dn eOutlier fpEC50 ± SEM, M (hp value) gEmax ± SEM, % (hp value) iRA 
SMPa FGKGGAYDPLSAGFTD 1602.72 1603.53 25.02  12 4/72 -7.70 ± 0.07 114.7 ± 3.0 1.0 
SMPb FGMGGAYDPLSAGFTD 1605.74 1605.68 28.20  5 0/30 -7.53 ± 0.09 (0.1418) 106.9 ± 3.0 (0.2497) 0.49 
SMPc FGMGGAYDPLSAGFTE 1619.77 1619.70 28.45  5 0/30 -7.38 ± 0.09 (0.0056) 108.1 ± 3.9 (0.2197) 0.39 
*SMPd GFLHGPDDPLSTSFVDGD 1875.97 1875.84 27.39  5 0/30 -6.33 ± 0.16 (†CBD) 82.61 ± 11.2 (0.2164) 0.0088 
SMPcocktail [SMPa] : [SMPb] : [SMPc] : [SMPd] = 12 : 5 : 1 : 1  5 0/30 -7.48 ± 0.09 (0.0514) 124.3 ± 4.0 (0.0598) 0.80 
aMrcalc., calculated average molecular mass by ExPASy Compute pI/Mw; bMrobs., observed protonated molecular mass on MALDI-TOF mass spectrophotometer; cRT, 
retention times determined on a reverse-phase C18 Vydac column (4.6 × 250 mm) with a linear gradient of 5 to 45% acetonitrile/0.1% TFA at a flow rate of 1.0 ml/min in 
40 min; dthe number of separate experiments; enumber of automatically eliminated data points per total number of data points for tested peptide; fpEC50, the negative 
logarithm of the half maximal effective concentration of the peptide, were calculated from the best-fit of a sigmoidal dose-response curve with a four-parameter logistic 
equation; gEmax, efficacy refers to the best-fit top value on a dose-response curve produced by the test peptide and is expressed as a relative percentage of the maximum 
contraction by 1 µM ACh; hp values were obtained by comparison of the best-fit values of pEC50 or Emax between SMP and SMP-like peptides using Extra sum-of-squares 
F test and the values less than 0.05 (p < 0.05) were considered as statistically significant; iRA, relative activity was calculated as the ratio of the concentration of SMP and 
analog peptides required to produce equieffective responses to a half-maximal SMP response. *maximal relaxing activity was not reached at a peptide concentration of 10-
5 M. †CBD (cannot be determined) because the value was ambiguous and accurate deconvolution was not possible. 
